Skip to Content

Summit Therapeutics PLC ADR SMMT

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Summit Therapeutics PLC is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of medicines for indications for which there inadequate or no therapies. It also conducts clinical programs focused on the genetic disease Cuchenne muscular dystrohy and the infectious disease Clostridium difficile infection. The company has drug development segment. Its all assets are located in the United Kingdom.

Contact
136a Eastern Avenue, Milton Park
Abingdon, Oxon, OX14 4SB, United Kingdom
T +44 1235443939
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 63